NASDAQ:INZY
Inozyme Pharma, Inc. Stock News
$4.60
-0.130 (-2.75%)
At Close: May 17, 2024
Inozyme Pharma (NASDAQ:INZY) Coverage Initiated by Analysts at Needham & Company LLC
08:14am, Friday, 03'rd Dec 2021 Dakota Financial News
Needham & Company LLC initiated coverage on shares of Inozyme Pharma (NASDAQ:INZY) in a research report report published on Monday, Analyst Ratings Network reports. The firm issued a buy rating and a $23.00 target price on the stock. Separately, Zacks Investment Research lowered shares of Inozyme Pharma from a buy rating to a hold rating []
Nuveen Asset Management LLC Raises Position in Inozyme Pharma, Inc. (NASDAQ:INZY)
09:20am, Tuesday, 30'th Nov 2021 Dakota Financial News
Nuveen Asset Management LLC lifted its stake in shares of Inozyme Pharma, Inc. (NASDAQ:INZY) by 122.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 47,394 shares of the companys stock after purchasing an additional 26,102 shares during the period. Nuveen []
Inozyme Pharma (INZY) Stock: $23 Price Target From Needham
06:09am, Tuesday, 30'th Nov 2021
The shares of Inozyme Pharma Inc (NASDAQ: INZY) have received a $23 price target from Needham. These are the details.
Zacks Investment Research Lowers Inozyme Pharma (NASDAQ:INZY) to Hold
10:32am, Sunday, 21'st Nov 2021 Dakota Financial News
Zacks Investment Research downgraded shares of Inozyme Pharma (NASDAQ:INZY) from a buy rating to a hold rating in a report published on Wednesday, Zacks.com reports. According to Zacks, Inozyme Pharma Inc. is a biopharmaceutical company. It engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue and skeleton diseases. The companys product []
Inozyme Pharma Announces Dosing of First Patient in First-in-Human Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency
12:30pm, Monday, 15'th Nov 2021 GlobeNewswire Inc.
- Preliminary biomarker and safety data expected in the first half of 2022 - - Preliminary biomarker and safety data expected in the first half of 2022 -
Inozyme Pharma Announces Dosing of First Patient in First-in-Human Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency
12:30pm, Monday, 15'th Nov 2021 ForexTV
Preliminary biomarker and safety data expected in the first half of 2022 BOSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced that the first patient has been dosed in its first-in-human Phase 1/2 clinical The post Inozyme Pharma Announces Dosing of First Patient in First-in-Human Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency appeared first on ForexTV .
Wall Street Analysts Believe Inozyme Pharma, Inc. (INZY) Could Rally 257%: Here's is How to Trade
11:33am, Friday, 12'th Nov 2021
The average of price targets set by Wall Street analysts indicates a potential upside of 256.5% in Inozyme Pharma, Inc. (INZY). While the effectiveness of this highly sought-after metric is questionab
Inozyme Pharma to Present at Upcoming Investor Conferences
07:30am, Thursday, 11'th Nov 2021
BOSTON, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal m
Inozyme Pharma Announces Presentation of Data from ENPP1 Deficiency Development Program at the ASBMR 2021 Annual Meeting
07:30am, Monday, 04'th Oct 2021
- Natural History Study shows ectopic calcification and/or cardiovascular disease could serve as distinguishing characteristics of ENPP1 Deficiency in some children with rickets -
INZY Stock: Why It Increased Today
03:11pm, Wednesday, 22'nd Sep 2021
The stock price of Inozyme Pharma Inc (NASDAQ: INZY) increased by over 15% during intraday trading today. This is why it happened.
Inozyme Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference
07:30am, Wednesday, 22'nd Sep 2021
BOSTON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal
Inozyme Pharma Reports Q2 2021 Financial Results and Provides Business Highlights
06:00am, Wednesday, 11'th Aug 2021
- Received Orphan Drug Designation from the European Medicines Agency for INZ-701 for the treatment of ABCC6 Deficiency –
Inozyme Pharma to Participate in 2021 Wedbush PacGrow Healthcare Virtual Conference
07:30am, Wednesday, 04'th Aug 2021
BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, toda
Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of ABCC6 Deficiency
07:30am, Wednesday, 21'st Jul 2021
INZ-701 was previously granted Orphan Drug Designation by the U.S. Food and Drug Administration and European Medicines Agency for ENPP1 Deficiency INZ-701 was previously granted Orphan Drug Designatio
Inozyme Pharma Announces Appointment of Gayle Gironda as Senior Vice President, Human Resources
07:30am, Tuesday, 13'th Jul 2021
BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, toda